Parkinson’s disease is a progressive neurodegenerative disorder which results in depletion of dopamine within the substantia nigra pars compacta in the central nervous system. Parkinson’s disease primarily affects the motor system causing the classical symptoms of bradykinesia, tremor and rigidity.
In addition, Parkinson’s disease results in non-motor symptoms such as depression and dementia which can worsen over time.
The exact cause of Parkinson’s disease is unknown and there are no disease-modifying treatments.
Featured Learning Zones
The COMT inhibition in Parkinson's Disease Learning Zone contains key information, expert opinion and interactive learning to highlight the benefit to patients of early levodopa treatment and diagnosis of the motor fluctuations which signal disease progression and prompt adjunctive treatment. Also detailing key efficacy and safety data for the approved COMT inhibitors to help inform your treatment decisions.
Latest Clinical Guidelines, Trials and Journals
This study attempts to observe the effectiveness and safety of aripiprazole in hospitalized patients with acute schizophrenia episode, and to compare the different drug regimens that may be involved in order to clarify the characteristics...
These updated guidelines on the management of variceal haemorrhage have been commissioned by the Clinical Services and Standards Committee (CSSC) of the British Society of Gastroenterology (BSG) under the auspices of the liver section of the BSG.
Latest news and insights
A new retrospective data analysis published in Kidney Medicine shows that a higher percentage of hemodialysis patients prescribed Velphoro (sucroferric oxyhydroxide chewable tablets), from Fresenius Medical, achieved target serum phosphorous levels of less than or equal to 5.5 mg/dL compared to those patients who
Takeda Pharmaceutical Co announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use granted a positive opinion for the extension of the marketing authorization of Adcetris (brentuximab vedotin) and recommended its approval in combination with CHP (cyclophosphamide,
Novo Nordisk announced that the New England Journal of Medicine published results of a phase III trial evaluating the investigational use of Saxenda (liraglutide) injection 3.0 mg in adolescents (aged 12– 18) with obesity.